<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-13T18:31:08Z</responseDate>
  <request identifier="oai:figshare.com:article/33770596" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33770596</identifier>
        <datestamp>2026-09-15T04:24:19Z</datestamp>
        <setSpec>category_696</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Data Sheet 1_Cancer stem cell programs S-nitrosylation and deubiquitination of FoxP3 protein to promote regulatory T cell differentiation.pdf</dc:title>
          <dc:creator>Xiyu Liu (1700959)</dc:creator>
          <dc:creator>Jiaxin Lei (143514)</dc:creator>
          <dc:creator>Xinhang Jiang (182904)</dc:creator>
          <dc:creator>Lingyi Li (6819935)</dc:creator>
          <dc:creator>Longhao Yu (24911848)</dc:creator>
          <dc:creator>Gengxue Wang (24911851)</dc:creator>
          <dc:creator>Kaixun Guo (24911854)</dc:creator>
          <dc:creator>Zhenke Wen (219096)</dc:creator>
          <dc:creator>Yan Wang (15435)</dc:creator>
          <dc:subject>Genetic Immunology</dc:subject>
          <dc:subject>CSCs</dc:subject>
          <dc:subject>deubiquitination</dc:subject>
          <dc:subject>Foxp3</dc:subject>
          <dc:subject>regulatory T cell</dc:subject>
          <dc:subject>S-nitrosylation</dc:subject>
          <dc:description>Background&lt;p&gt;Cancer stem cells (CSCs) are critical drivers of tumor progression and therapeutic resistance in non-small cell lung cancer (NSCLC). However, how CSCs remodel the immunosuppressive tumor microenvironment (TME) of NSCLC remains largely unclear.&lt;/p&gt;Methods&lt;p&gt;Flow cytometry was performed to evaluate the immunomodulatory effects of NSCLC CSCs on T cell differentiation. RNA-sequencing-based metabolic profiling was conducted to identify pivotal metabolic pathways activated in CSCs. Mitochondrial reactive oxygen species (ROS) encapsulated in CSC-derived exosomes were quantified, and the molecular mechanism by which exosomal ROS modulates intracellular nitric oxide (NO) production and FoxP3 post-translational modifications in T cells was further explored. Patient-derived organoids (PDOs) were utilized as a preclinical model to verify the therapeutic potential of glutamine metabolism targeting.&lt;/p&gt;Results&lt;p&gt;NSCLC CSCs potently induced tumor immunosuppression by promoting regulatory T (Treg) cell differentiation. Mechanistically, hyperactive glutamine metabolism in CSCs substantially increased mitochondrial ROS generation. Exosomal ROS secreted by CSCs was transferred to T cells, thereby elevating intracellular NO synthesis. Increased NO further triggered S-nitrosylation and deubiquitination of FoxP3, which ultimately stabilized FoxP3 expression and facilitated Treg cell differentiation. In NSCLC PDO models, pharmacological inhibition of glutamine metabolism reversed the immunosuppressive T cell phenotype and efficiently suppressed PDO growth.&lt;/p&gt;Conclusion&lt;p&gt;NSCLC CSCs mediate TME immunosuppression via a glutamine metabolism-dependent regulatory axis. Exosomal ROS-initiated FoxP3 post-translational modification is a novel mechanism underlying CSC-driven Treg differentiation. This study reveals an unreported immune evasion pathway in NSCLC and identifies glutamine metabolism as a viable therapeutic target for overcoming tumor immunosuppression.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-15T04:24:19Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.3389/fimmu.2026.1961819.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Data_Sheet_1_Cancer_stem_cell_programs_S-nitrosylation_and_deubiquitination_of_FoxP3_protein_to_promote_regulatory_T_cell_differentiation_pdf/33770596</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
